Disruption of ERα signalling pathway by PPARγ agonists: Evidences of PPARγ-independent events in two hormone-dependent breast cancer cell lines

Breast Cancer Research and Treatment

Volumn 112, Issue 3, 2008, Pages 437-451

  Lecomte, Julie ^a   Flament, Stéphane ^a   Salamone, Stéphane ^b   Boisbrun, Michel ^b   Mazerbourg, Sabine ^a   Chapleur, Yves ^b   Grillier Vuissoz, Isabelle ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b NANCY UNIVERSITÉ   (France)

Author keywords

Breast cancer; ER ; PPAR ; PPAR independent; Troglitazone

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALITRETINOIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CIGLITAZONE; COMPLEMENTARY DNA; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PROTEASOME INHIBITOR; ROSIGLITAZONE; SMALL INTERFERING RNA; TROGLITAZONE; ANTINEOPLASTIC AGENT; CHROMAN DERIVATIVE; LIGAND; PROTEASOME;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; BREAST TUMOR; DOSE RESPONSE; DRUG POTENTIATION; GENE SILENCING; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR ALPHA; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; PPAR GAMMA; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 56549115139     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-007-9886-z     Document Type: Article

References (58)

1. DJ Mangelsdorf C Thummel M Beato 1995 The nuclear receptor superfamily: the second decade Cell 83 835 839
2. I Isseman S Green 1990 Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 645 650
3. SA Kliewer BM Forman B Blumberg 1994 Differential expression and activation of a family of murine peroxisome proliferators-activated receptors Proc Natl Acad Sci USA 91 7355 7359
4. C Dreyer G Krey H Keller 1992 Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors Cell 68 879 887
5. I Issemann RA Prince JD Tugwood 1993 The retinoid X receptor enhances the function of the peroxisome proliferator activated receptor Biochimie 75 251 256
6. DJ Mangelsdorf RM Evans 1995 The R × R heterodimers and orphan receptors Cell 83 841 850
7. NJ McKenna BW O'Malley 2002 Minireview: nuclear receptor coactivators-an update Endocrinology 43 2461 2465
8. W Yang C Rachez LP Freedman 2000 Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators Mol Cell Biol 20 8008 8017
9. SR Thoennes PL Tate TM Price 2000 Differential transcriptional activation of peroxisome proliferator-activated receptor gamma by omega-3 and omega-6 fatty acids in MCF-7 cells Mol Cell Endocrinol 160 67 73
10. BM Forman P Tontonoz J Chen 1995 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma Cell 83 803 812
11. SA Kliewer JM Lenhard TM Willson 1995 A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation Cell 83 813 819
12. JM Lehmann JM Lenhard BB Oliver 1997 Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs J Biol Chem 272 3406 3410
13. BM Spiegelman 1998 PPAR-gamma: adipogenic regulator and thiazolidinedione receptor Diabetes 47 507 514
14. KY Kim SS Kim HG Cheon 2006 Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells Biochem Pharmacol 72 530 540
15. JO Nwankwo ME Robbins 2001 Peroxisome proliferator-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cells Prostaglandins Leukot Essent Fatty Acids 64 241 245
16. E Elstner C Muller K Koshizuka 1998 Ligands for peroxisome proliferators-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice Proc Natl Acad Sci 95 8806 8811
17. E Mueller P Sarraf P Tontonoz 1998 Terminal differentiation of human breast cancer through PPARγ Mol Cell 1 465 470
18. RG Mehta E Williamson MK Patel 2000 A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions J Natl Cancer Inst 92 418 423
19. MH Fenner E Elstner 2005 Peroxisome proliferator-activated receptor-g ligands for the treatment of breast cancer Expert Opin Investig Drugs 14 557 568
20. F Yin S Wakino Z Liu 2001 TGZ inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators Biochem Biophys Res Commun 286 916 922
21. S Goetze XP Xi H Kawano 1999 PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells J Cardiovasc Pharmacol 33 798 806
22. X Xin S Yang J Kowalski 1999 Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo J Biol Chem 274 9116 9121
23. HJ Burstein GD Demetri E Mueller 2003 Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand TGZ as treatment for refractory breast cancer: a phase II study Breast Cancer Res Treat 79 391 397
24. LD Yee N Williams P Wen 2007 Pilot study of rosiglitazone therapy in women with breast cancer:effects of short-term therapy on tumor tissue and serum marker Clin Cancer Res 13 246 252
25. NJ Nelson 2006 Migrant studies aid the search for factors linked to breast cancer risk J Natl Cancer Inst 98 436 438
26. S Massarweh R Schiff 2006 Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signalling crosstalk Endocr Relat Cancer 13 S15 S24
27. X Wang MW Kilgore 2002 Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells Mol Cell Endocrinol 194 123 133
28. D Bonofiglio S Gabriele S Aquila 2005 Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signalling in breast cancer cells Clin Cancer Res 11 6139 6147
29. JW Huang CW Shiau YT Yang 2005 Peroxisome proliferator-activated receptor γ-independent ablation of cyclin D1 by Thiazolidinediones and their derivatives in breast cancer cells Mol Pharmacol 67 1342 1348
30. CW Shiau CC Yang SK Kulp 2005 Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma Cancer Res 65 1561 1569
31. F Turturro E Friday R Fowler 2004 TGZ acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor γ-independent mechanism in breast cancer-derivated cell lines Clin Cancer Res 10 7022 7030
32. CE Clay A Monjazeb J Thorburn 2002 15-Deoxy-delta 12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells J Lipid Res 43 1818 1828
33. J Pandhare SK Cooper JM Phang 2006 Proline oxidase, a proapoptotic gene, is induced by TGZ. Evidence for both peroxisome proliferator-activated receptor γ-dependent and -independent mechanisms J Biol Chem 281 2044 2052
34. JM Seargent EA Yates JH Gill 2004 GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation Br J Pharmacol 143 933 937
35. T Wang J Xu X Yu 2006 Peroxisome proliferator-activated receptor gamma in malignant diseases Crit Rev Oncol Hematol 58 1 14
36. C Qin R Burghardt R Smith 2003 Peroxisome proliferators-activated receptor-γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells Cancer Res 63 958 964
37. T Suzuki S Hayashi Y Miki 2006 Peroxisome proliferator-activated receptor γ in human breast carcinoma: a modulator of estrogenic actions Endocr Relat Cancer 13 233 250
38. HJ Kim JY Kim Z Meng 2007 15-deoxy-Delta 12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-alpha via covalent modification of DNA-binding domain Cancer Res 67 2595 2602
39. D Boschi GC Tron L Lazzarato 2006 NO-Donor phenols: a new class of products endowed with antioxidant and vasodilator properties J Med Chem 49 2886 2897
40. JW Huang CW Shiau J Yang 2006 Development of small-molecule cyclin D1-ablative agents J Med Chem 49 4684 4689
41. A Fazzari MG Catalano A Comba 2001 The control of progesterone receptor expression in MCF-7 breast cancer cells: effects of estradiol and sex hormone-binding globulin (SHBG) Mol Cell Endocrinol 172 31 36
42. T Okubo Y Yokoyama K Kano 2001 ER-dependent estrogenic activity of parabens assessed by proliferation of human breast cancer MCF-7 cells and expression of ERalpha and PR Food Chem Toxicol 39 1225 1232
43. R Morosetti DJ Park AM Chumakov 1997 A novel, myeloid transcription factor, C/EBP epsilon, is upregulated during granulocytic, but not monocytic, differentiation Blood 90 2591 2600
44. JR Weng CY Chen JJ Pinzone 2006 Beyond peroxisome proliferator-activated receptor gamma signalling: the muti-facets of the antitumor effect of thiazolidinediones Endocr Relat Cancer 13 401 413
45. G Leclercq M Lacroix I Laïos 2006 Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells Curr Cancer Drug Targets 6 39 64
46. E Elstner EA Williamson C Zang 2002 Novel therapeutic approach: ligands for PPAR-γ and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells Breast Cancer Res Treat 74 155 165
47. N Etique S Flament J Lecomte 2007 Ethanol-induced ligand-independent activation of ERα mediated by cyclic AMP/PKA pathway: an in vitro study on MCF-7 breast cancer cells Int J Oncol 31 6 1509 1518
48. H Keller F Givel M Perroud 1995 Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid × receptor and estrogen receptor through estrogen response elements Mol Endocrinol 9 794 804
49. DH Wolf W Hilt 2004 The proteasome: a proteolytic nanomachine of cell regulation and waste disposal Biochim Biophys Acta 1695 19 31
50. M Callige H Richard-Foy 2006 Ligand-induced estrogen receptor alpha degradation by the proteasome: new actors? Nucl Recept Signal 4 e004
51. BR Henke SG Blanchard MF Brackeen 1998 N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents J Med Chem 41 5020 5036
52. CD Allred MW Kilgore 2005 Selective activation of PPARgamma in breast, colon, and lung cancer cell lines Mol Cell Endocrinol 235 21 29
53. C Qin D Morrow J Stewart 2004 A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes Mol Cancer Ther 3 3 247 260
54. MA Lea M Sura C Desbordes 2004 Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) gamma agonists and antagonists Anticancer Res 24 2765 2771
55. KL Schaefer H Takahashi VM Morales 2006 PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPAR delta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells Int J Cancer 120 702 713
56. J Keelan R Helliwell B Nijmeijer 2001 15-deoxy-delta12,14-prostaglandin J2-induced apoptosis in amnion-like WISH cells Prostaglandins Other Lipid Mediat 66 265 282
57. D Bonofiglio S Aquila S Catalano 2006 Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells Mol Endocrinol 20 3083 3092
58. Talbert DR, Allred CD, Zaytseva YY et al (2007) Transactivation of ERalpha by RZG induces proliferation in breast cancer cells. Breast Cancer Res Treat (in press)